The Pierre Fabre-backed antibody therapy developer has closed a series A round featuring new and founding investors.

Pharmaceutical and cosmetics producer Pierre Fabre has acquired a stake in US-based autoimmune and inflammatory drug developer ValenzaBio in connection with a $70m series A round for the latter.

Investment and financial services group Fidelity Management & Research, Surveyor Capital, Ikarian Capital, Janus Henderson Investors and Opaleye Management supplied the series A funds while Pierre Fabre took its stake through a recent license and commercialisation deal.

ValenzaBio’s pipeline includes VB119, a monoclonal antibody being developed to treat autoantibody-mediated diseases such…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn